Cory Ahonen

MIST, Inc. is a private company that specializes in the installation, revamp, and routine maintenance of tower internals. The company is based in Pleasant Plain, OH. The company provides an efficient union workforce devoted to safety and successful project completion. The company is committed to teamwork, honesty, hard work, determination, and responsibility. The company has experience working with various industries such as oil refineries, chemical plants, steel mills, and breweries. MIST has recently partnered with Sitedocs to upload all of their safety forms into their platform, making the transition into the digital age.

Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million.

Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.